JP2008295444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008295444A5 JP2008295444A5 JP2007265917A JP2007265917A JP2008295444A5 JP 2008295444 A5 JP2008295444 A5 JP 2008295444A5 JP 2007265917 A JP2007265917 A JP 2007265917A JP 2007265917 A JP2007265917 A JP 2007265917A JP 2008295444 A5 JP2008295444 A5 JP 2008295444A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- primer
- antisense
- base
- primer set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense effect Effects 0.000 claims 16
- 108091034117 Oligonucleotide Proteins 0.000 claims 14
- 230000000295 complement effect Effects 0.000 claims 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 3
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 101150068690 eml4 gene Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 101150023956 ALK gene Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 claims 1
- 241000258955 Echinodermata Species 0.000 claims 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007265917A JP4303303B2 (ja) | 2006-10-11 | 2007-10-11 | Ｅｍｌ４−ａｌｋ融合遺伝子 |
| US12/100,595 US7605131B2 (en) | 2006-10-11 | 2008-04-10 | EML4-ALK fusion gene |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006277718 | 2006-10-11 | ||
| JP2007120670 | 2007-05-01 | ||
| CA 2598893 CA2598893C (en) | 2006-10-11 | 2007-08-24 | Eml4-alk fusion gene |
| JP2007265917A JP4303303B2 (ja) | 2006-10-11 | 2007-10-11 | Ｅｍｌ４−ａｌｋ融合遺伝子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009035918A Division JP5172736B2 (ja) | 2006-10-11 | 2009-02-18 | Ｅｍｌ４−ａｌｋ融合遺伝子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008295444A JP2008295444A (ja) | 2008-12-11 |
| JP2008295444A5 true JP2008295444A5 (cg-RX-API-DMAC7.html) | 2009-02-12 |
| JP4303303B2 JP4303303B2 (ja) | 2009-07-29 |
Family
ID=39277176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007265917A Active JP4303303B2 (ja) | 2006-10-11 | 2007-10-11 | Ｅｍｌ４−ａｌｋ融合遺伝子 |
| JP2009035918A Active JP5172736B2 (ja) | 2006-10-11 | 2009-02-18 | Ｅｍｌ４−ａｌｋ融合遺伝子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009035918A Active JP5172736B2 (ja) | 2006-10-11 | 2009-02-18 | Ｅｍｌ４−ａｌｋ融合遺伝子 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7728120B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2116553B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4303303B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE450547T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2598893C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007003543D1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2515170T3 (cg-RX-API-DMAC7.html) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| DK2016089T3 (da) * | 2006-04-14 | 2014-04-22 | Cell Signaling Technology Inc | Gendefekter og mutant-alk-kinase i humane faste tumorer |
| EP2447360A1 (en) * | 2006-04-14 | 2012-05-02 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| AU2009215168A1 (en) * | 2008-02-12 | 2009-08-20 | Dana-Farber Cancer Institute | Fish assay for EML4 and ALK fusion in lung cancer |
| JP2009219728A (ja) * | 2008-03-18 | 2009-10-01 | Daito Giken:Kk | 遊技台 |
| PL2300013T5 (pl) | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2432900A4 (en) * | 2009-05-15 | 2012-11-21 | Insight Genetics Inc | METHOD AND COMPOSITIONS RELATED TO ALK FUSIONS FOR DIAGNOSIS AND TREATMENT OF CANCER |
| EP2487250A4 (en) * | 2009-10-06 | 2013-03-20 | Fujirebio Kk | METHOD FOR DETECTING FUSION GENES |
| WO2011087709A2 (en) | 2009-12-22 | 2011-07-21 | Quest Diagnostics Investments Incorporated | Eml4-alk translocations in lung cancer |
| EP2540822B1 (en) * | 2010-02-22 | 2017-05-03 | Fujirebio Inc. | Method for identification of oncogene, method for establishment of cell capable of expressing oncogene, and method for screening for oncogene-targeting substance |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| WO2011130635A2 (en) * | 2010-04-16 | 2011-10-20 | Response Genetics, Inc. | Primers, probes, methods and kits for the detection of eml4-alk variants |
| WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| RU2573392C3 (ru) | 2010-08-20 | 2021-06-24 | Чугаи Сейяку Кабусики Кайся | Композиция, содержащая тетрациклические соединения |
| KR101583589B1 (ko) * | 2010-09-02 | 2016-01-08 | 구루메 다이가쿠 | 단분자 ｄｎａ로 형성되는 환상 ｄｎａ의 작성 방법 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| JP5769952B2 (ja) * | 2010-11-12 | 2015-08-26 | 株式会社Ｌｓｉメディエンス | Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法 |
| WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
| MX2013008791A (es) * | 2011-02-02 | 2013-10-07 | Irm Llc | Metodos para usar inhibidores de alk. |
| US20140296181A1 (en) * | 2011-04-07 | 2014-10-02 | Coferon, Inc. | Methods of modulating oncogenic fusion proteins |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| CN103890175B (zh) | 2011-08-31 | 2015-12-09 | 学校法人久留米大学 | 在dna分子的环化中仅选择由单分子形成的环化dna的方法 |
| PL2838998T3 (pl) | 2012-04-18 | 2018-04-30 | Cell Signaling Technology, Inc. | EGFR i ROS1 w nowotworze |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9084456B1 (en) * | 2012-05-28 | 2015-07-21 | Jack Zemer | Linkage for jewelry components |
| US9597348B2 (en) | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| US20150342979A1 (en) * | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Dot1l inhibitors for use in the treatment of leukemia |
| HK1211235A1 (en) | 2013-02-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP6534930B2 (ja) | 2013-07-26 | 2019-06-26 | 公益財団法人がん研究会 | Ｎｔｒｋ３融合体の検出法 |
| JP6806440B2 (ja) * | 2013-10-29 | 2021-01-06 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2015064621A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2015111716A1 (ja) | 2014-01-24 | 2015-07-30 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| PL3135287T3 (pl) | 2014-04-25 | 2025-03-31 | Chugai Seiyaku Kabushiki Kaisha | Preparat zawierający związek tetracykliczny w dużej dawce |
| JP6873698B2 (ja) | 2014-04-25 | 2021-05-19 | 中外製薬株式会社 | ４環性化合物の新規結晶 |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
| US10597725B2 (en) * | 2014-09-01 | 2020-03-24 | Arkray, Inc. | Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same |
| JP7015171B2 (ja) | 2016-01-15 | 2022-02-02 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JP6740172B2 (ja) * | 2017-05-02 | 2020-08-12 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| WO2020006314A1 (en) * | 2018-06-27 | 2020-01-02 | City Of Hope | Modification of small rnas for therapeutic uses |
| CN112384223B (zh) | 2018-06-29 | 2024-08-27 | 中外制药株式会社 | 含有难溶性碱性药剂的药物组合物 |
| JP7385191B2 (ja) * | 2019-08-30 | 2023-11-22 | 学校法人同志社 | Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬 |
| JP2020156481A (ja) * | 2020-04-06 | 2020-10-01 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| JPWO2023074785A1 (cg-RX-API-DMAC7.html) | 2021-10-28 | 2023-05-04 | ||
| IL317839A (en) | 2022-07-04 | 2025-02-01 | Chugai Pharmaceutical Co Ltd | Combination drug |
| CN119789871A (zh) | 2022-08-30 | 2025-04-08 | 中外制药株式会社 | 并用药物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001034785A1 (en) | 1999-11-11 | 2001-05-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel metalloprotease having aggrecanase activity |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| SI2287156T1 (sl) | 2003-08-15 | 2013-09-30 | Novartis Ag | 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema |
| WO2005097765A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| DK2016089T3 (da) | 2006-04-14 | 2014-04-22 | Cell Signaling Technology Inc | Gendefekter og mutant-alk-kinase i humane faste tumorer |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
-
2007
- 2007-08-24 CA CA 2598893 patent/CA2598893C/en active Active
- 2007-08-27 US US11/845,498 patent/US7728120B2/en active Active
- 2007-10-11 ES ES09006058.3T patent/ES2515170T3/es active Active
- 2007-10-11 ES ES07254044T patent/ES2335368T3/es active Active
- 2007-10-11 JP JP2007265917A patent/JP4303303B2/ja active Active
- 2007-10-11 AT AT07254044T patent/ATE450547T1/de not_active IP Right Cessation
- 2007-10-11 DE DE200760003543 patent/DE602007003543D1/de active Active
- 2007-10-11 EP EP20090006058 patent/EP2116553B1/en active Active
-
2008
- 2008-04-10 US US12/100,595 patent/US7605131B2/en active Active
-
2009
- 2009-02-18 JP JP2009035918A patent/JP5172736B2/ja active Active
- 2009-05-15 US US12/466,920 patent/US7964710B2/en active Active
-
2011
- 2011-04-13 US US13/086,245 patent/US8197818B2/en active Active
-
2012
- 2012-05-10 US US13/468,730 patent/US9029521B2/en active Active
-
2015
- 2015-03-10 US US14/643,181 patent/US9932589B2/en active Active
-
2017
- 2017-11-13 US US15/810,918 patent/US20180066266A1/en not_active Abandoned